Amylyx director exercises options for 50,000 shares
Amylyx Pharmaceuticals, Inc. (AMLX) director Karen Firestone reported exercising stock options to acquire common shares on August 31, 2026.
Rhea-AI Filing Summary
Amylyx Pharmaceuticals, Inc. (AMLX) director Karen Firestone reported exercising stock options to acquire common shares on August 31, 2026. She exercised two fully vested stock option grants covering a total of 50,000 shares of Common Stock, at exercise prices of $1.76 and $5.05 per share, respectively. The filing does not show her post-transaction share balances, and no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
50,000 shares exercised/converted
Exercise
4 txns
Insider
Firestone Karen
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1 | 25,000 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F1 | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $1.76 | $44K |
| Exercise | Common Stock | 25,000 | $5.05 | $126K |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 116,900 shares (Direct)
Footnotes (1)
- F1. This option is fully vested and exercisable.
Key Figures
Options exercised at $1.76: 25,000 shares
Options exercised at $5.05: 25,000 shares
Total shares acquired via exercise: 50,000 shares
+2 more
5 metrics
Options exercised at $1.76
25,000 shares
Stock option exercise into Common Stock at $1.76 per share on August 31, 2026
Options exercised at $5.05
25,000 shares
Stock option exercise into Common Stock at $5.05 per share on August 31, 2026
Total shares acquired via exercise
50,000 shares
Aggregate Common Stock received from both option exercises on August 31, 2026
Exercise price (first grant)
$1.76 per share
Conversion or exercise price for one stock option grant expiring June 5, 2034
Exercise price (second grant)
$5.05 per share
Conversion or exercise price for one stock option grant expiring June 4, 2035
Key Terms
Stock Option (right to buy), derivative security, Common Stock, Rule 10b5-1
4 terms
Stock Option (right to buy) financial
"The reporting person held a Stock Option (right to buy) that was exercised"
derivative security financial
"Transactions coded as an exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"Underlying security title reported as Common Stock acquired upon exercise"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Rule 10b5-1 regulatory
"A document-level checkbox indicates Rule 10b5-1 trading plan status"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did AMLX director Karen Firestone report?
Karen Firestone reported exercising stock options to acquire 50,000 shares of Amylyx Pharmaceuticals Common Stock on August 31, 2026, through two separate option exercises.
How many Amylyx Pharmaceuticals (AMLX) options did Karen Firestone exercise?
She exercised options covering a total of 50,000 shares of Amylyx Pharmaceuticals Common Stock, split into two blocks of 25,000 shares each from separate option grants.
What were the exercise prices for the AMLX options exercised by Karen Firestone?
The reported stock option exercises were for 25,000 shares at $1.76 per share and 25,000 shares at $5.05 per share of Amylyx Pharmaceuticals Common Stock.
Was Karen Firestone’s AMLX option exercise under a Rule 10b5-1 trading plan?
No. The filing indicates no Rule 10b5-1 trading plan applies to these transactions; the plan-related checkbox is not marked as being used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
